DENVER, Oct. 7, 2005 (PRIMEZONE) -- Medical International Technology, Inc. ("MIT") (OTCBB:MDIR) (http://www.mitcanada.ca), a developer and manufacturer of patented needle-free jet injectors for human and animal inoculation, announces a decision by the Board of Directors to affect a one-for-ten reverse split of the company's issued and outstanding shares. This will begin the process that, if completed successfully, is intended to place MIT in a better position to achieve the financing required to expand the company's worldwide marketing and production operations.
MIT CANADA, with offices in Montreal, is a subsidiary of Denver, Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass vaccinations.
Karim Menassa, President On Behalf of the Board of Directors Medical International Technology, Inc.
This press release is available on the Medical International Investor Relations site for investor questions, commentary and feedback. Investors are asked to visit http://www.agoracom.com/IR/MIT . Alternatively, investors can e-mail their questions or comments directly to MDIR@agoracom.com or asked to be placed on the Medical International investor e-mail list to receive all future press releases directly.
The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development and acquisition of new product lines and services, government approval processes, the impact of competitive products or pricing a technological changes, the effect of economic conditions and other uncertainties, and the risk factors set forth from time to time in the company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. Medical International Technology, Inc. takes no obligation to update or correct forward-looking statements.